Last reviewed · How we verify
AN2728 Topical Ointment, 0.5% QD
AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin cells when applied topically.
AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin cells when applied topically. Used for Psoriasis (topical treatment), Atopic dermatitis (topical treatment).
At a glance
| Generic name | AN2728 Topical Ointment, 0.5% QD |
|---|---|
| Sponsor | Pfizer |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels, which suppresses the production of pro-inflammatory mediators such as TNF-α and IL-23 in immune and skin cells. This mechanism reduces the inflammatory cascade underlying psoriasis and other inflammatory skin conditions. The topical formulation delivers the drug directly to affected skin with minimal systemic exposure.
Approved indications
- Psoriasis (topical treatment)
- Atopic dermatitis (topical treatment)
Common side effects
- Application site irritation
- Application site burning
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2728 Topical Ointment, 0.5% QD CI brief — competitive landscape report
- AN2728 Topical Ointment, 0.5% QD updates RSS · CI watch RSS
- Pfizer portfolio CI